Lexeo Acquires Mantle Therapeutics, Expands Friedreich Ataxia Pipeline
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The acquisition and collaborations modestly strengthen Lexeo's pipeline in a rare disease niche, likely supporting positive sentiment for LXEO shares but with limited broader market impact given the small deal size. The transactions signal continued biotech M&A activity in gene therapy and rare disease, though the financial scale is too small to move sector-wide indices.
Lexeo Therapeutics, Inc. (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including a definitive agreement to acquire privately held clinical-stage company Ajax Therapeutics, Inc. The acquisition adds multiple FA programs to Lexeo's pipeline, led by LX3010 (formerly MTL-104), a clinical-stage oral combination therapy, along with three preclinical assets (LX3030, LX3050, LX3070) targeting frataxin protein restoration. Under the terms, Lexeo will pay approximately $8.3 million in upfront consideration in cash and equity, with up to $13 million in success-based clinical and regulatory milestone payments, for a total potential consideration of $21.3 million. The transaction is expected to close in the third quarter of 2026. In addition, Lexeo announced three new research collaborations: a research agreement with Weill Cornell Medicine to evaluate intracisternal administration of LX2006, an option agreement with Ajax Therapeutics for an exclusive license to VTX-PID, and an option agreement with Apertura Gene Therapy for a blood-brain barrier-crossing capsid. Lexeo's lead program, LX2006, remains its highest priority, with the pivotal SUNRISE-FA 2 study continuing to enroll and topline data expected in the second half of 2027. The company stated these initiatives are within its existing balance sheet capacity, with cash runway guidance unchanged into 2028. CEO James Townsend emphasized that the deals broaden Lexeo's technology platform and strengthen its leadership in FA. LXEO stock traded at $4.23, up 3.90%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard